Einzeltreffer — DigiBib

Disclosed herein are recombinant CMV vectors which may comprise a heterologous antigen that can repeatedly infect an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may comprise a deleterious mutation in the US11 glycoprotein or a homolog thereof.

Titel:	CMV Glycoproteins and Recombinant Vectors
Link:	View record in USPTO Patent Applications (Volltext)
Veröffentlichung:	2021
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20210222195 Publication Date: July 22, 2021 Appl. No: 16/934495 Application Filed: July 21, 2020 Claim: 1. A cytomegalovirus (CMV) vector comprising: a first nucleic acid sequence encoding US2, US3, or US6 or a homolog thereof; and a second nucleic acid sequence encoding an exogenous Mycobacterium tuberculosis antigen; wherein the vector does not encode a functional US11 protein or homolog thereof. Claim: 2. The vector of claim 1, wherein the first nucleic acid sequence encodes US2, US3, and US6. Claim: 3. The vector of claim 2, wherein a nucleic acid encoding a US11 ORF is deleted. Claim: 4. The vector of claim 1, further comprising a third nucleic acid sequence encoding US11 and wherein the nucleic acid sequence encoding US11 comprises a point mutation, a frameshift mutation, and/or a deletion of one or more nucleotides of the nucleic acid sequence encoding US11. Claim: 5-6. (canceled) Claim: 7. A method of eliciting an immune response to an antigen in a subject, the method comprising administering an effective amount of the vector of claim 1. Claim: 8. (canceled) Claim: 9. The method of claim 7, wherein the subject was previously exposed to CMV. Claim: 10. The method of claim 11, wherein the subject is a human or a rhesus macaque. Claim: 11. The method of claim 7, wherein the CMV vector comprises one or more of a point mutation in a nucleic acid sequence encoding US11, a frameshift mutation in the nucleic acid sequence encoding US11, a deletion of all or part of the nucleic acid sequence encoding US11, or an antisense or RNAi construct that inhibits the expression of US11. Claim: 12. The method of claim 7, wherein administering comprises intravenous, intramuscular, intraperitoneal, or oral administration of the CMV vector. Claim: 13. The vector of claim 1, wherein the first nucleic acid sequence encodes a US2 comprising the amino acid sequence of SEQ ID NO: 1, a US3 comprising the amino acid sequence of SEQ ID NO: 2, or a US6 comprising the amino acid sequence of SEQ ID NO:3. Claim: 14. The vector of claim 1, wherein the first nucleic acid sequence encodes a US2 comprising the amino acid sequence of SEQ ID NO: 1, a US3 comprising the amino acid sequence of SEQ ID NO:2, and a US6 comprising the amino acid sequence of SEQ ID NO: 3. Claim: 15. The vector of claim 1, wherein the functional US11 protein comprises the amino acid sequence of SEQ ID NO: 4. Claim: 16. The vector of claim 2, wherein the functional US11 protein comprises the amino acid sequence of SEQ ID NO:4. Claim: 17. The vector of claim 3, wherein the functional US11 protein comprises the amino acid sequence of SEQ ID NO: 4. Claim: 18. The vector of claim 1, wherein the vector does not encode a functional US8 or a functional US10 protein, or homolog thereof. Claim: 19. The vector of claim 18, wherein the vector comprises a deletion of all of the nucleic acid sequence encoding US8-US11. Claim: 20. The vector of claim 1, wherein the vector further comprises a promoter operably linked to the second nucleic acid sequence encoding an exogenous Mycobacterium tuberculosis antigen, wherein the promoter is a constitutive promoter, an inducible promoter, a non-viral promoter, or a viral promoter. Current International Class: 12; 61; 12

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

CMV Glycoproteins and Recombinant Vectors